CGEM

In April 2026, the FDA accepted the New Drug Application (NDA) for zipalertinib. On August 6, 2026, the company reported a wider-than-expected loss for fiscal Q2 2026, missing analyst estimates. Wedbush increased its price objective to $42.00 with an 'outperform' rating on August 13, 2026, and TD Cowen upgraded the stock to a 'strong-buy' rating on August 24, 2026. Insider Jennifer Michaelson sold 8,000 shares on September 8, 2026. Positive results from the Phase 3 REZILIENT3 trial of Zipalertinib plus chemotherapy were reported on September 13, 2026, demonstrating a 6-month median progression-free survival benefit. On September 14, 2026, Cullinan Therapeutics announced the first patient dosed in a planned registrational Phase 2 study of CLN-049. The stock experienced significant drops on September 23-24, 2026, due to a delayed arthritis update and lingering zipalertinib safety worries. BTIG Research reiterated a 'buy' rating and set a $40.00 target price on September 25, 2026. On September 28, 2026, the company outlined Q4 milestones for its T cell engager pipeline. The NDA submission for zipalertinib plus chemotherapy in first-line EGFR Exon 20 Insertion Mutation NSCLC was initiated on October 1, 2026. HC Wainwright reiterated a Buy rating and a $35 price target on October 2, 2026, while Weiss Ratings restated a 'sell (d-)' rating. On October 8, 2026, the company announced the first patient dosed in a planned registrational Phase 2 study of CLN-049. The stock's 1-year change as of October 7, 2026, was +165.4%, but its 1-month change was -29.2%.